Xtant Medical Earnings Call Highlights Profitability Turnaround

Xtant Medical Holdings Inc ((XTNT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Xtant Medical Holdings’ latest earnings call painted a cautiously optimistic picture, with management emphasizing a successful return to profitability and sharply improved cash generation. Executives acknowledged that 2026 will show a headline revenue decline as divestitures and nonrecurring license deals roll off, but stressed that higher-margin biologics and a leaner cost base position the company for healthier, more sustainable growth.

Solid Top-Line Finish to 2025 Despite Transaction Drag

Xtant reported Q4 2025 revenue of $32.4 million, up 3% from $31.5 million a year earlier, even though the early closing of the Coflex/Paradigm sale trimmed roughly $2 million from the quarter. That modest growth capped a year in which the company had to juggle portfolio reshaping while keeping underlying demand intact.

Full-Year Sales Land Near Top of Guidance Range

For 2025, revenue climbed 14% to $133.9 million from $117.3 million in 2024, landing toward the upper end of prior guidance of $131 million to $135 million. The performance shows that Xtant could expand the business meaningfully while simultaneously exiting noncore assets and preparing for a shift toward in-house biologics.

Return to Profitability and Strong Adjusted EBITDA Turnaround

Xtant swung from a $16.5 million loss in 2024 to $5.0 million of net income in 2025, or $0.03 per share, marking a key inflection point for investors focused on earnings. Adjusted EBITDA similarly flipped from a roughly $2.3 million loss to $16.3 million for the year, with Q4 adjusted EBITDA rising to $1.9 million and quarterly net income turning positive at $57,000.

Gross Margin Expansion Underscores Higher-Quality Revenue Mix

Gross margin for 2025 improved to 62.9% from 58.2% in 2024, a roughly 470-basis-point gain driven by a richer mix and scaling of operations. This expansion came despite increased inventory-related charges, suggesting that underlying profitability of core products is improving as the portfolio shifts to higher-margin offerings.

Cash Position Strengthens and Leverage Comes Down

The balance sheet looks notably healthier, with cash, cash equivalents and restricted cash rising to $17.3 million at year-end 2025, up from $6.2 million a year earlier. After year-end, Xtant received additional proceeds of about $10.7 million and had an $8.2 million promissory note satisfied from the Companion Spine deal, allowing further debt reduction and reinforcing financial flexibility.

Strategic Divestiture Refocuses Business on Biologics

The sale of the noncore Coflex interlaminar stabilization assets and international Paradigm Spine entities to Companion Spine closed in early December at a final purchase price of roughly $21.4 million. Management argued that this transaction sharpened Xtant’s focus on higher-margin biologics while also boosting the capital base to reinvest in core growth areas.

Product Pipeline Expansion Targets Full Orthobiologic Spectrum

Xtant highlighted several key launches, including nanOss Strata, a synthetic bone graft, and CollagenX, a bovine collagen particulate, alongside ongoing launches of Trivium, OsteoVive Plus and OsteoFactor Pro. Executives said surgeon feedback has been excellent and noted that these products now give Xtant coverage across all five major orthobiologic categories.

Sales Force Build-Out Aims to Accelerate Biologics Growth

The company doubled the number of regional sales representatives in 2025, signaling a major commercial push behind its biologics line. Looking to 2026, management plans to invest further in national accounts resources to win more institutional business and convert pipeline interest into sustained revenue growth.

Operating Expense Discipline Supports Margin Story

Total operating expenses fell to $77.0 million in 2025 from $80.3 million in 2024, reflecting tighter cost control even as the company expanded its commercial footprint. Sales and marketing expense declined to $45.5 million from $49.2 million, helped by lower commissions and trimmed compensation related to headcount, which should support future margin resilience.

Guidance Prioritizes Cash Generation and Self-Sufficiency

For 2026, Xtant guided revenue to a lower $95 million to $99 million range on a pro-forma basis, reflecting the divestiture and roll-off of license deals, but reiterated its goal of remaining free-cash-flow positive without needing external capital. Management expects sequential quarter-over-quarter revenue growth through the year, gross margins in the low-60% range and organic biologics traction to gradually offset lost nonrecurring revenue.

Headline Revenue Drop Masks Structural Changes

The 2026 revenue outlook implies a 26% to 29% year-over-year decline from 2025’s $133.9 million, which management tied primarily to divested Coflex and related hardware sales and the expiration of nonrecurring Q-code and amniotic membrane license revenue. Around $18.7 million of 2025 license revenue will not repeat, creating a near-term drag on reported growth despite improvements in the quality of earnings.

Biologics and Hardware Face Near-Term Pressure

Biologics revenue is expected to decline by low double digits in Q1 2026 versus Q1 2025, largely due to the lost amnio product, while remaining hardware is projected to fall roughly mid-teens after adjusting for the divestiture. For the full year, that residual hardware stream is expected to trend toward a high-teens decline as Xtant progressively deemphasizes lower-margin mechanical products.

Inventory and Compensation Costs Temper Margin Gains

Q4 2025 results absorbed a $1.3 million inventory charge tied to the Cortera Fixation System, part of broader excess and obsolete inventory expenses that shaved about 260 basis points off gross margin for the year. General and administrative costs also rose, with Q4 G&A increasing to $7.3 million from $5.7 million and full-year G&A edging up to $29.5 million, largely on higher compensation-related expenses.

Early Divestiture Close Weighed on Q4 Revenue

The Companion Spine transaction closed roughly one month earlier than management originally anticipated, in early December, which management estimated cost the company about $2 million of Q4 2025 revenue. While this timing hurt near-term reported sales, it also accelerated access to proceeds that have already been deployed to strengthen the balance sheet.

Channel Transition Brings Execution and Timing Risk

Management flagged that OEM, white-label and distributor arrangements are evolving post-divestiture, with OEM accounting for around 20% of biologics revenue today. The shift away from amnio, Q-code and certain OEM relationships introduces timing uncertainty on how fast branded Xtant biologics can backfill lost volume, adding an execution overhang despite a stronger strategic focus.

Forward-Looking View: Sequential Growth on a Smaller Base

Looking ahead, Xtant expects 2026 to be a reset year, with lower reported revenue but improving mix, margins and cash generation as biologics become the growth engine. Management is guiding to sequential quarterly growth, modestly lower but still solid gross margins in the low-60% range and continued investment in commercial resources to drive organic expansion while keeping the company financially self-sufficient.

The call left investors with a nuanced but constructive message: while the top line will step down materially in 2026 as divested and nonrecurring revenue disappears, the underlying business is more profitable, more focused and better capitalized than a year ago. If Xtant can execute on its biologics ramp and manage channel transitions smoothly, the current revenue reset may set the stage for higher-quality growth in the years ahead.